Severe Breakthrough COVID-19 Cases during Six Months of Delta Variant (B.1.617.2) Domination in Poland

The emergence of a highly transmissible and a more pathogenic B.1.617.2 (delta) variant of SARS-CoV-2 has brought concern over COVID-19 vaccine efficacy and the increased risk of severe breakthrough infections. The objective of this study was to assess the frequency and the clinical characteristics...

Descripción completa

Detalles Bibliográficos
Autores principales: Rzymski, Piotr, Pazgan-Simon, Monika, Kamerys, Juliusz, Moniuszko-Malinowska, Anna, Sikorska, Katarzyna, Wernik, Joanna, Zarębska-Michaluk, Dorota, Supronowicz, Łukasz, Sobala-Szczygieł, Barbara, Skrzat-Klapaczyńska, Agata, Simon, Krzysztof, Piekarska, Anna, Czupryna, Piotr, Pawłowska, Małgorzata, Brzdęk, Michał, Jaroszewicz, Jerzy, Kowalska, Justyna, Renke, Marcin, Flisiak, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9025315/
https://www.ncbi.nlm.nih.gov/pubmed/35455306
http://dx.doi.org/10.3390/vaccines10040557

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9025315/
https://www.ncbi.nlm.nih.gov/pubmed/35455306
http://dx.doi.org/10.3390/vaccines10040557

Ejemplares similares